This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old | MicrobiomeTrials
← Back to trials NCT07187375
Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2025-09-30Est. Completion: 2029-09-06
Enrollment target: 7 participantsLocations Neurocrine Clinical Site, Berlin, Germany Neurocrine Clinical Site, Düsseldorf, Germany Neurocrine Clinical Site, Heidelberg, Germany Other microbiome trials you might be interested in Congenital Adrenal Hyperplasia (CAH) Familial Male-Limited Precocious Puberty (FMPP)
This study will evaluate and gather information in patients with genetic causes of too much androgen (male-like hormone)…
Washington D.C., United States
Attention Deficit Hyperactivity Disorder Schizophrenia Attention Deficit Disorder With Hyperactivity
Magnetic Resonance Imaging (MRI) unlike X-rays and CT-scans does not use radiation to create a picture. MRI use as the n…
Bethesda, United States